Objective: Despite highly expensive treatments, lupus nephritis remains a major cause of morbidity and mortality in patients with relapsing or refractory lupus nephritis. Meanwhile, experimental studies indicate that curcumin attenuates both the binding of autoantibodies from systemic lupus erythematosus patients to their cognate antigens and also the inflammatory responses of tumor necrosis factor-alpha-stimulated human endothelial cells. Therefore, in this study we investigated effect(s) of oral curcumin supplementation on patients suffering from relapsing or refractory lupus nephritis.
L UPUS NEPHRITIS IS an autoimmune dis-
ease characterized by polyclonal B-cell hyperactivity and defective T-cell function, which is responsive to immunosuppressive and steroids therapy, but often pursues a relapsing and, in a minority, a refractory course. This necessitates highly expensive treatments, such as calcineurin inhibitors, plasmapheresis, intravenous immunoglobulins, anti-CD20 antibody, anti-CD22 antibody, and stem cell transplantation, which are not affordable by most of our patients; however, those who can afford such an expensive treatment are associated with increasing side effects such as infection and malignancies. [1] [2] [3] [4] [5] [6] Meanwhile, it has been shown in experimental studies that curcumin attenuates inflammatory responses of tumor necrosis factor-alpha-stimulated human endothelial cells. 7 Also, in vitro studies indicate that heat-solubilized curcumin/turmeric decreases binding of autoantibodies from systemic lupus erythematosus (SLE) patients (to a maximum of 52/70%) to their cognate antigens. 8 Thus, in this study, the effect(s) of oral turmeric supplementation on 24 patients with relapsing or refractory biopsy-proven lupus nephritis was investigated.
Methods
All 239 patients with SLE under regular follow-up in Lupus Clinic of Hafez Hospital, Out-patient Department of Shiraz University of Medical Sciences, were observed and examined. All cases with biopsy-proven lupus nephritis, done before therapy and at the time of diagnosis of renal flare, and classified according to the The International Society of Nephrology/Renal Pathology Society (ISN/RPS) classification, who had relapsing or refractory course, were selected for this study. [9] [10] [11] Decreasing C3 and C4 levels and an increasing anti-double-stranded deoxyribonucleic acid (ds DNA) antibody titer associated with clinical renal deterioration were used to define renal flare. Failure to improve serological markers and clinical renal manifestations after 8 weeks' therapy with high dosage of corticosteroid (3 consecutive daily 1 g pulses of methyl prednisolone for class IV lupus nephritis, and 1 mg/kg/day of prednisone for class III and V lupus nephritis) plus monthly 1 g intravenous cyclophosphamide or 2 g of oral mycophenolate mofetil was defined as refractory lupus nephritis. Exclusion criteria were normal serological markers (C3 and C4 levels, and anti-ds DNA antibody titer) and being in clinical renal remission with stable clinical renal manifestations. Also, patients who refused to have kidney biopsy, or had malnutrition, malabsorption, chronic liver disease, recurrent or relapsing infection, or malignancies, or failed to sign a written informed consent when risks associated with the trial was carefully outlined for them, were excluded. The remaining 24 patients who had followed a protracted course with periods of remissions and exacerbations were randomized into 2 groups (the trial group and the control group). All 12 patients in the control group had relapsing lupus nephritis; only 1 of the 12 patients in the trial group had refractory course and the remaining 11 cases had relapsing lupus nephritis. A total of 15 patients with focal lupus nephritis (,50% of glomeruli) and active and/or chronic lesions were classified as class III; 6 cases who had diffuse lupus nephritis ($50% of glomeruli) and segmental or global lupus nephritis with active and/or chronic lesions were classified as class IV; and 3 patients with membranous lupus nephritis were classified class V. 10 In addition to their immunosuppressive (corticosteroids and cyclophosphamide or mycophenolate mofetil) and antihypertensive drugs (mainly angiotensinconverting enzyme inhibitors and angiotensin receptor blockers), each patient in the trial group received a safe dose of turmeric (1 capsule with each meal, containing 500 mg turmeric of which 22.1 mg was the active ingredient curcumin, 3 capsules daily) for 3 months, whereas the control group received 3 capsules, identical in color and size, containing starch for the same 3-month period. 12 All investigators who were part of the study were blinded to the type of supplementation the patients were receiving during the trial. The capsules containing turmeric or starch were given to the patients in a separate room by a nurse who was not a member of the research team. All patients followed their usual diet and no dietary change was made by the investigators regarding their protein and/or salt intake during the trial. Turmeric rhizomes were obtained from the Indian market and powdered rhizomes were encapsulated by Amin Drug Manufacturing Company (Boharan City, Kelishad, Esfehan, Iran), using hard gelatin capsules. Curcumin as standard was obtained from Sigma Aldrich (Saint Louis, MO). Acetonitrile, methanol, and acetic acid were high performance liquid chromatography (HPLC) grade (Merck-Germany). Reagents grade water (Purelab, Ultra High Quality, ELGA, UK) was used throughout. Curcumin level of turmeric was measured by methods described elsewhere. 13 Antibodies specific for anti-ds DNA and the levels of complement components (C3 and C4) were measured using enzymelinked immunosorbent assay.
14 Estimated glomerular filtration rate was calculated according to Modification of Diet in Renal Disease formula. 15 Patients were seen weekly by 2 of the investigators for detection of any side effects related to the turmeric supplementation, blood pressure measurement, and clinical evaluation during the 3 months of the trial. Just before and at 1, 2, and 3 months of the trial, the blood urea nitrogen, serum creatinine, 24 hours urine protein (Biuret method), and creatinine were measured. Each patient served as a self control, when her/ his pre-and postsupplementation values were compared. This study complies with the deceleration of Helsinki and was approved by the local ethics committee.
Statistical Analysis
Data were analyzed using Statistical Package for the Social Sciences software version 15.0 (SPSS Inc, Chicago, IL). Chi-square test was used to analyze categorical There was no significant difference in patient's characteristics at baseline between the 2 groups of the control and the trial (P . .05).
variables such as age, gender, antihypertensive drugs, and class of lupus nephritis between the 2 groups. Quantitative data were presented as mean 6 standard deviation and compared by Mann-Whitney test in the 2 groups as nonparametric test. The data variations were performed before and after administration of turmeric by Wilcoxon signed-ranks test as nonparametric test of paired t-test. All tests were 2-sided, and P value ,.05 was considered significant.
Results
Patients' characteristics at baseline are compared in Table 1 , which show no significant difference between the control and the trial groups. As demonstrated in Table 2 , there was no significant difference in anti-ds DNA antibody and C3 levels with turmeric supplementation between the trial and the control groups as well as pre-and postturmeric supplementation values. As shown in Table 3 , urinary protein excretion decreased *There was significant difference in the trial group when comparing pre-and post-turmeric supplementation values at 3 months (P 5 .02).
†There was significant difference between pre-and post-turmeric supplementation values at 1, 2, and 3 months in the trial group (P , .01).
‡There was significant difference in turmeric supplementation values after 2 months between the 2 groups (control and trial groups) (P 5 .04).
significantly as pre-and post-turmeric supplementation values at 1, 2, and 3 months of the study were compared in the trial group. Also, a significant decrease in urinary protein excretion was noted on comparing the 2 months post-turmeric supplementation values between the trial and the control groups. In addition, systolic blood pressure decreased significantly comparing pre-and post 3 months turmeric supplementation values in the trial group. Values with significant changes such as urinary protein excretion, systolic blood pressure, and hematuria, are shown in Figures 1-3 , respectively, with 1 line joining before and after 3 months values for each of the 12 patients in the control and the trial groups. No adverse effect related to the turmeric supplementation was seen during 3 months of the trial.
Discussion
Proteinuria is an ominous prognostic sign in renal evolution of lupus nephritis. 16 Figure 2 . Comparison of systolic blood pressure in 24 patients with refractory or relapsing lupus nephritis randomized into 2 groups (trial and the control groups) before and after 3 months of turmeric administration, which shows a significant decrease in systolic blood pressure in the trial group when comparing pre-and postturmeric supplementation values (P 5 .02). Figure 1 . Comparison of 24 hours urinary protein excretion in 24 patients with refractory or relapsing lupus nephritis randomized into 2 groups (trial and the control groups) before and after 3 months of turmeric administration, which shows a significant decrease in urinary protein excretion in the trial group when comparing preand post-turmeric supplementation values (P , .009).
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damage, and deterioration of renal function in patients with lupus nephritis. 16 The extent of persistent proteinuria correlates relatively well with the rate of decline in creatinine clearance, interestingly, limiting proteinuria results in a slower renal function impairment and possibly reversal of fibrotic lesions. [20] [21] [22] [23] [24] However, in the present study which is carried out for the first time in human beings, we investigated the effect of 3 months of oral turmeric supplementation on the proteinuria at 1, 2, and 3 months of the trial in 24 patients with relapsing or refractory lupus nephritis. We found a significant decrease in proteinuria in the trial group comparing pre-and post-turmeric supplementation values at 1, 2, and 3 months. Although turmeric supplementation had no significant effect on the immunological defect associated with lupus nephritis, which is an underlying factor for initiation of the disease, this finding might imply that turmeric might be effective in lowering proteinuria, and thus slowing the progression of chronic kidney disease (CKD) irrespective of the specific cause of the renal lesion. To support this notion, in experimental studies, curcumin, the major component found in turmeric spice, has been reported to ameliorate diabetic nephropathy via blocking cytokines, including the transforming growth factor-b signaling cascade in renal cells, to prevent renal fibrosis and delay apoptosis by decreasing in messenger ribonucleic acid expression of tumor necrosis factor-a and, and to improve oxidative stressinduced renal injury. [25] [26] [27] [28] Although this study is randomized and placebo-controlled, it is limited by the small number of our patients and by the fact that we did not take the measurements of markers regarding inflammation and/or oxidative stress. Also, it is a short-term trial; moreover, we did not perform dose-response curves to justify use of higher doses of turmeric, and hence, a low but safe dose of turmeric supplementation was used in this study. Considering that all of those aforementioned factors might have contributed to unchanged renal function in the present study, 12 it seems wise that long-term trials with higher doses of turmeric justified by dose-response curves should be carried out to find out whether antiproteinuric effect of turmeric can improve renal function tests in patients suffering from relapsing or refractory lupus nephritis.
Arterial hypertension is an adverse prognostic sign in patients with lupus nephritis. [17] [18] [19] [29] [30] [31] To the authors' knowledge, there has been no study in medical literature to address the effect of turmeric on arterial hypertension in patients suffering from relapsing or refractory lupus nephritis. However, for the first time in this study, on comparing pre-and post-turmeric supplementation values in the trial group, we found that with oral turmeric supplementation, systolic blood pressure decreased significantly because of unknown mechanism. Regarding that, a considerable body of data has demonstrated a strong relationship between higher levels of blood pressure and faster CKD progression. 32 It seems wise to suggest that turmeric supplementation might be able to delay or even Figure 3 . Comparison of urinary number of red blood cells per high power field in 24 patients with refractory or relapsing lupus nephritis randomized into 2 groups (trial and the control groups) before and after 3 months of turmeric administration, which shows a significant decrease in urinary number of red blood cells per high power field in the trial group when comparing pre-and postturmeric supplementation values (P , .02).
prevent progression of CKD of various origins by decreasing both hypertension and urinary protein excretion; however, long-term trials are needed to clarify the issue.
It is well known that anti-ds DNA antibody and C3 levels are sensitive tools for predicting exacerbations as well as activity in SLE patients [33] [34] [35] [36] [37] [38] ; however, we found no significant change in anti-ds DNA antibody and C3 levels with oral turmeric supplementation, whereas the amount of proteinuria, hematuria, and also the level systolic blood pressure decreased significantly in the trial group at the end of the 3 months of turmeric supplementation. The mechanisms involved in the observed effects of turmeric in this study have not been explored. However, no measurements of markers regarding inflammation and/or oxidative stress have been performed in this study. Thus, we can only speculate that improvement in cardinal clinical manifestations of relapsing and refractory lupus nephritis might have stemmed from antiinflammatory and/or antioxidative stress effects of turmeric. 7, 8, [25] [26] [27] Nonetheless, the issue remains to be proved.
In conclusion, the results of this study indicate that short-term oral turmeric supplementation is a beneficial, safe, and effective adjuvant therapy for patients suffering from relapsing or refractory lupus nephritis. However, long-term trials with higher doses of turmeric are needed to clarify its effect on the renal function of such patients and the rate of progression of CKD of various origins.
